- WuXi Biologics (药明生物)
Focus: Global-leading CDMO (Contract Development & Manufacturing Organization).
Why Top Tier: Unmatched scale with over 600,000 liters of planned bioreactor capacity globally. The undisputed leader in revenue and client base, serving hundreds of global pharma and biotech companies. A technology powerhouse with proprietary platforms for cell line development and continuous manufacturing.
2. BeiGene (百济神州)
Focus: Fully integrated global biotech (R&D, Manufacturing, Commercialization).
Why Top Tier: One of China’s most innovative companies with a deep internal R&D pipeline. Their large-scale biologics facility in Guangzhou supports global supply of their blockbuster PD-1 inhibitor, tislelizumab. A leader in bringing China-discovered novel drugs to the US and EU markets.
3. Innovent Biologics (信达生物)
Focus: Integrated biopharmaceutical company.
Why Top Tier: A pioneer in China’s biologics innovation wave. Has a strong partnership with Eli Lilly and a robust commercial portfolio led by Tyvyt® (sintilimab). Their large-scale, state-of-the-art manufacturing facilities in Suzhou are designed to meet international standards (FDA, EMA).
4. Shanghai Henlius (复宏汉霖)
Focus: Biopharmaceutical company (a subsidiary of Fosun Pharma).
Why Top Tier: China’s leader in biosimilars, with multiple products (like Hanlikang® and Hanquyou®) already on the market. Has built a comprehensive platform from R&D to commercialization. Their Songjiang facility is a large-scale, flexible manufacturing site.
5. GenScript Biotech (金斯瑞生物科技)
Focus: Life sciences CRO/CDMO, with a strong focus on cell and gene therapy (through its subsidiary Legend Biotech and CDMO arm GenScript ProBio).
Why Top Tier: A global leader in gene synthesis and a powerhouse in cell therapy. Legend Biotech’s CAR-T product, Carvykti (ciltacabtagene autoleucel), developed with J&J, is a world-class therapy. Their CDMO arm is a key player in the advanced therapeutics space.
6. Jiangsu Hengrui Medicine (江苏恒瑞医药)
Focus: Large, traditional pharma giant with a major and growing biologics division.
Why Top Tier: One of China’s largest and most R&D-intensive pharmaceutical companies. Has aggressively invested in building a robust biologics pipeline (mAbs, ADCs) and the large-scale manufacturing infrastructure in Suzhou and Lianyungang to support it.
7. CanSino Biologics (康希诺生物)
Focus: Vaccine research, development, and manufacturing.
Why Top Tier: A globally recognized innovator in vaccines. Known for its adenovirus vector technology platform (used in its Convidecia COVID-19 vaccine). Has strong capabilities in rapid development and large-scale manufacturing of complex biologics (viral vectors).
8. Kangtai Biological (康泰生物)
Focus: Vaccine manufacturer.
Why Top Tier: One of China’s largest and most established vaccine producers. Has a diverse portfolio of in-market vaccines and a significant manufacturing footprint. Plays a critical role in China’s national immunization program.
9. Walvax Biotechnology (沃森生物)
Focus: Vaccine R&D and manufacturing.
Why Top Tier: A major player in vaccines, particularly known for its proprietary 13-valent pneumococcal conjugate vaccine (PCV13). Has strong in-house R&D and significant commercial-scale manufacturing capabilities.
10. Luoxin Pharmaceutical (罗欣药业) / Mabwell (迈威生物)
Note: This spot is highly competitive. I’ve included two contenders representing different strengths.
Luoxin: A traditional pharma with a strong, fast-growing biologics CDMO arm (Luoxin Biologics) that is gaining significant traction and scale.
Mabwell: An emerging, innovation-driven biotech with a full industry chain platform and several novel biologics (mAbs, ADCs) in late-stage clinical development, representing the “next wave” of Chinese biomanufacturers.
Key Categories & Honorable Mentions:
Pure-Play CDMOs: WuXi Biologics is the giant. Others gaining ground include Hangzhou Just Biotherapeutics (acquired by WuXi), **Boji Medical (勃林格殷格翰生物药业, a global CDMO’s China site), and Polaris (博瑞生物).
Vaccine Specialists: Sinovac and Sinopharm (CNBG) are enormous in volume for inactivated and traditional vaccines, though often listed separately from innovative biologics.
Advanced Therapy (CGT) Leaders: IASO Biotherapeutics (CAR-T), JW Therapeutics (CAR-T), and Yingli Pharmaceutical are key in cell and gene therapy manufacturing.
Disclaimer: The ranking can vary depending on the metric (revenue, pipeline value, capacity). This list reflects a composite view of scale, innovation, and market impact in the biologics sector specifically, excluding traditional small-molecule pharma.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
